A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL)

被引：0
|
作者：
Ahluwalia, Manmeet Singh
Peereboom, David M.
Ozair, Ahmad
Khosla, Atulya Aman
Rauf, Yasmeen
Nayak, Lakshmi
Ciolfi, Marci
Alban, Tyler
Grabowski, Matthew
Rayman, Pat
Diaz, Marcella
Lathia, Justin
Lee, Eudocia Quant
Wen, Patrick Y.
Reardon, David A.
机构：
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] William Beaumont Univ Hosp, Dept Internal Med, Royal Oak, MI USA
[4] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Cleveland Clin Lerner Res Inst, Cleveland, OH USA
[7] Dana Farber Canc Inst, Div Neurooncol, Boston, MA 02115 USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2072
引用
收藏
页数：1
相关论文
共 50 条
  • [1] RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT
    Ahluwalia, Manmeet
    Khosla, Atulya
    Rauf, Yasmeen
    Peereboom, David
    Wen, Patrick Y.
    Reardon, David A.
    [J]. NEURO-ONCOLOGY, 2022, 24 : 64 - 64
  • [2] RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
    Ahluwalia, Manmeet
    Peereboom, David
    Schilero, Cathy
    Forst, Deborah
    Wong, Eric
    Wen, Patrick
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2018, 20 : 234 - 234
  • [3] A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)
    Ahluwalia, Manmeet
    Fallah, Jaleh
    Peereboom, David
    Schilero, Cathy
    Ali, Assad
    Forst, Deborah
    Wong, Eric
    Wen, Patrick
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2019, 21 : 220 - 220
  • [4] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
    Weathers, Shiao-Pei S.
    Han, Stan Xiaosi
    Liu, Diane D.
    Conrad, Charles A.
    Gilbert, Mark R.
    Loghin, Monica Elena
    O'Brien, Barbara Jane
    Penas-Prado, Marta
    Puduvalli, Vinay K.
    Tremont-Lukats, Ivo
    Yung, W. K. Alfred
    De Groot, John Frederick
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
    Weathers, Shiao-Pei
    Han, Xiaosi
    Liu, Diane D.
    Conrad, Charles A.
    Gilbert, Mark R.
    Loghin, Monica E.
    O'Brien, Barbara J.
    Penas-Prado, Marta
    Puduvalli, Vinay K.
    Tremont-Lukats, Ivo
    Colen, Rivka R.
    Yung, W. K. Alfred
    de Groot, John F.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (03) : 487 - 494
  • [6] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
    Shiao-Pei Weathers
    Xiaosi Han
    Diane D. Liu
    Charles A. Conrad
    Mark R. Gilbert
    Monica E. Loghin
    Barbara J. O’Brien
    Marta Penas-Prado
    Vinay K. Puduvalli
    Ivo Tremont-Lukats
    Rivka R. Colen
    W. K. Alfred Yung
    John F. de Groot
    [J]. Journal of Neuro-Oncology, 2016, 129 : 487 - 494
  • [7] RANDOMIZED PHASE II OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM). NIVOLUMAB BENEFITS OLDER POPULATION
    Ahluwalia, Manmeet
    Peereboom, David
    Rauf, Yasmeen
    Wen, Patrick
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2021, 23 : 52 - 52
  • [8] Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
    Ahluwalia, Manmeet Singh
    Rauf, Yasmeen
    Li, Hong
    Wen, Patrick Y.
    Peereboom, David M.
    Reardon, David A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (RGBM)
    Ahluwalia, Manmeet
    Peereboom, David
    Rauf, Yasmeen
    Lathia, Justin
    Alban, Tyler
    Schilero, Cathy
    Ciolfi, Marci
    LaForest-Roys, Corey
    Nayak, Lakshmi
    Lee, Eudocia
    Wen, Patrick
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2020, 22 : 35 - 35
  • [10] VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma
    Menon, Nandini Sharrel
    Shah, Minit Jalan
    Gupta, Tejpal
    Sridhar, Epari
    Chatterjee, Abhishek
    Dasgupta, Archya
    Sahu, Arpita
    Sawant, Riddhi
    Kapu, Venkatesh
    Trikha, Mehak
    Shah, Anokhi
    Peelay, Zoya Ravish
    Puranik, Ameya
    Dev, Indraja
    Jadhav, Monica
    Moiyadi, Aliasgar
    Shetty, Prakash
    Sahay, Ayushi
    Singh, Vikas Kumar
    Patil, Vijay Maruti
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA2064 - LBA2064
12345